Почетна › Плоскоклеточни карцином главе и врата › Ilinois › Chicago
Kliničke studije za Плоскоклеточни карцином главе и врата u gradu Chicago, IL
29 studija za Плоскоклеточни карцином главе и врата traži učesnike na lokacijama u gradu Chicago i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Тражи се учесникФаза 2
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Тражи се учесникФаза 2
- Northwestern University, Chicago
- University of Illinois, Chicago
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Тражи се учесникФаза 3
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Тражи се учесникФаза 1/2
- University of Illinois Cancer Center, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Тражи се учесникФаза 1
- University of Chicago Hospital, Chicago
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Тражи се учесникФаза 3
- Advocate Illinois Masonic Medical Center, Chicago
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Тражи се учесникФаза 1/2
- The University of Chicago Medical Center (UCMC), Chicago
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Тражи се учесникФаза 3
- Rush University Medical Center Rush University Cancer Center Chicago, Chicago
- The University of Chicago Medical Center (UCMC), Chicago
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Тражи се учесникФаза 2/3
- Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133), Chicago
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Тражи се учесникФаза 2/3
- University of Illinois Cancer Center, Chicago
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
Тражи се учесникФаза 1/2
- The University of Chicago Medical Center - Oncology, Chicago
SMP-3124LP in Adults With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Тражи се учесникФаза 1
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 257378, Chicago
- University of Chicago Medical Center /ID# 258197, Chicago
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Тражи се учесникФаза 3
- University of Chicago, Chicago
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Тражи се учесникФаза 1
- Exelixis Clinical Site #26, Chicago
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Тражи се учесникФаза 1
- Northwestern University Feinberg School of Medicine, Chicago
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Тражи се учесникФаза 2
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Тражи се учесникОпсервациона студија
- Northwestern University Feinberg School of Medicine, Chicago
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Тражи се учесникФаза 1
- University of Chicago Medical Center /ID# 276638, Chicago
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Тражи се учесникФаза 2/3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Тражи се учесникФаза 2
- Northwestern University, Chicago
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Тражи се учесникФаза 1
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- University of Chicago Medical Center, Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Тражи се учесникФаза 1
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
Тражи се учесникФаза 2
- University of Chicago Comprehensive Cancer Center, Chicago
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
Тражи се учесникФаза 2/3
- The University of Chicago, Chicago
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Тражи се учесникФаза 3
- University of Illinois Cancer Center, Chicago
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
Тражи се учесникФаза 1
- The University of Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Тражи се учесникФаза 1
- The University of Chicago Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Тражи се учесникФаза 1
- University of Chicago, Chicago
Studije za Плоскоклеточни карцином главе и врата u drugim gradovima
- Houston, TX49 студија
- Nashville, TN43 студија
- Los Angeles, CA43 студија
- Boston, MA42 студија
- New York City, NY42 студија
- St. Louis, MO32 студија
- Arlington, VA29 студија
- Philadelphia, PA25 студија
- Pittsburgh, PA23 студија
- Atlanta, GA22 студија
- New Haven, CT22 студија
- Dallas, TX22 студија
Ostale studije u gradu Chicago
- Рак дојке59 студија
- Немалоклетни карцином плућа59 студија
- Рак (све врсте)51 студија
- Рак простате45 студија
- Рак плућа43 студија
- Метастатски карцином42 студија
- Гојазност40 студија
- Рак јајника36 студија
- Колоректални карцином32 студија
- Шлог31 студија
- Гојазност29 студија
- Затајење срца28 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.